Original ArticlesTreatment-by-Histology Interaction Analyses in Three Phase III Trials Show Superiority of Pemetrexed in Nonsquamous Non-small Cell Lung Cancer
Key Words:
Cited by (0)
Disclosure: Giorgio Scagliotti, MD, Honoraria from AstraZeneca, Sanofi-Aventis, and Roche; Thomas Brodowicz, MD, Honoraria from Eli Lilly; Frances A. Shepherd, MD, Honoraria and stock ownership, Eli Lilly; Christoph Zielinski, MD, Honoraria: None during last 2 years; Johan Vansteenkiste, MD, Holder of the Eli-Lilly L. Hertel Chair at the Catholic University Leuven, Belgium (research funding); Christian Manegold, MD, Honorarium: Lilly, Roche, Merck-Darmstadt, Boehringer-Ingelheim, and AstraZeneca; Lorinda Simms, MSc, PStat, Employee of Eli Lilly and own Lilly stock; Frank Fossella, MD, None; Katherine Sugarman, MD, Employed by and holds stock in Eli Lilly and Company, the makers of pemetrexed; and Chandra P. Belani, MD, Consultant, Eli Lilly.